Sanara MedTech Signals Profitable Growth Momentum

Sanara MedTech ((SMTI)) has held its Q1 earnings call. Read on for the main highlights of the call.

Sanara MedTech struck an upbeat tone on its latest earnings call, highlighting robust top-line growth, expanding margins, and a turn to GAAP profitability. Management acknowledged rising costs, modest cash burn, and higher interest expense, but emphasized that strong commercial momentum and disciplined capital allocation put the company on firmer financial footing.

Strong Revenue Growth

Net revenue climbed 19% year over year in the first quarter of 2026, adding $4.4 million to the top line despite a seasonally slow period. The company credited the gain largely to surging demand for soft tissue repair products, notably CellerateRX Surgical and BIASURGE, which continue to deepen penetration in surgical settings.

GAAP Net Profitability Achieved

Sanara crossed an important milestone by posting GAAP net income from continuing operations of $0.4 million, or $0.04 per diluted share. That marks a sharp reversal from the prior-year loss of $0.6 million, or $0.07 per diluted share, signaling that revenue scale and cost structure improvements are starting to flow through to the bottom line.

Margin and Profitability Expansion

Gross profit increased by $4.3 million to $25.9 million in the quarter, with gross margin improving about 100 basis points to roughly 93% of net revenue. Operating income also strengthened, rising $1.8 million to $2.6 million, underscoring the leverage Sanara is gaining as sales accelerate against a relatively fixed cost base.

Adjusted EBITDA Improvement

Adjusted EBITDA jumped 58% year over year to $4.3 million, an increase of $1.6 million compared with the prior period. Management framed this improvement as evidence that the business model is maturing, with recurring procedure-driven revenue supporting stronger cash earnings and providing more flexibility for investment.

Commercial Footprint and Distribution Expansion

The company’s products are now contracted or approved in more than 4,000 hospitals and ambulatory surgery centers, reflecting steady progress with institutional buyers. Actual sales activity is occurring in over 1,400 facilities, up from more than 1,300 a year ago, while distributor agreements expanded to over 450 from 400, broadening Sanara’s route to market.

Sales Force Growth and Market Traction

Sanara expanded its sales team to 43 representatives, betting that a larger field presence will accelerate adoption across its portfolio. That investment is already showing signs of traction, as March recorded the strongest sales month in company history outside a one-off hurricane-related spike in 2024, reinforcing confidence in demand trends.

Improving Capital Allocation and Cash-Flow Discipline

Management highlighted a notable shift in capital discipline by covering all debt service in cash during the quarter, rather than using a mix of cash and payment-in-kind. The move signals improved free cash flow generation and supports the company’s stated priorities of funding organic growth and advancing targeted pipeline projects such as OsStic toward a planned 2027 launch.

Modest Cash Position and Operating Cash Use

Cash on hand decreased to $13.6 million at March 31, 2026, down from $16.6 million at year-end, reflecting ongoing investment and working capital needs. Net cash used in operating activities rose modestly to $2.5 million from $2.0 million a year earlier, a data point investors will watch as Sanara balances growth spending with its liquidity profile.

Rising Other Expense and Interest Costs

Other expense increased to $2.2 million from $1.4 million in the prior-year quarter, driven largely by higher interest and fees tied to the company’s term loan, as well as losses from equity-method investments. While not derailing profitability, these higher financing and investment costs pose a headwind that could weigh on net income if not offset by continued revenue and margin gains.

Operating Expense Increase

Operating expenses rose 12% year over year to $23.2 million, representing 83.6% of sales and reflecting heavier spending on selling, general, and administrative functions. Management noted that these higher SG&A costs are tied to commercial expansion and support infrastructure, partially balanced by lower research and development outlays during the quarter.

Reduced R&D in Quarter

Research and development expense slipped to $0.8 million, or 2.7% of sales, down from $0.9 million and 4.1% of sales in the year-ago period. Executives reiterated that they expect annual R&D to average 5% to 7% of sales, but the lower quarterly run rate could raise execution risk if underinvestment were to persist in future periods.

Operational Disruption and Seasonality

A three-day weather-related shutdown in January temporarily curtailed shipping activity, underscoring the operational sensitivity to unexpected disruptions. Management also reminded investors that the first quarter tends to be the slowest period of the year, suggesting that the strong results came despite seasonal and logistical headwinds.

New Hires and Contracts Not Yet Fully Accretive

Many of the newly hired sales representatives remain in ramp-up mode, with management estimating that it takes roughly six months for new reps to reach full productivity. Similarly, the recently added Vizient group purchasing relationship is still in early stages, requiring ongoing facility-level work before it can deliver its full contribution to revenue.

Forward-Looking Guidance and Outlook

Sanara reaffirmed its outlook for second-quarter 2026 net revenue of $28.5 million to $29.5 million, implying 10% to 14% year-over-year growth, and full-year 2026 revenue of $116 million to $121 million, or roughly 13% to 17% growth. Management anchored this guidance on strong first-quarter performance, expanding commercial reach, and a disciplined investment roadmap, while acknowledging ongoing seasonality, debt obligations, and the need to maintain adequate R&D funding.

Sanara MedTech’s latest earnings call painted a company moving from promise to execution, with strong growth and rising profitability offsetting concerns around cash usage and higher financing costs. For investors, the story now hinges on whether the enlarged sales force, broadened distribution, and disciplined capital strategy can sustain double-digit growth while keeping the balance sheet on a stable path.